Zumutor Biologics raises $7.3M Series B to advance cancer immunotherapy trials
What's the deal? Bengaluru- and US-based biotech startup Zumutor Biologics has raised $7.3M in a Series B round to advance clinical trials for its cancer immunotherapy drug ZM008. Existing investors Accel and Bharat Innovation FundDealroom has a profile for this one. Try Dealroom → participated alongside new backers Premji Invest and angel investors Ashish KacholiaDealroom has a profile for this one. Try Dealroom → and Raj Dandu.
Founded in 2013 by Kavitha Iyer Rodrigues, Zumutor develops drugs that activate the body's natural killer (NK) cells to attack tumours. ZM008, which it describes as a first-in-class NK cell checkpoint therapy, entered human trials in 2024.
The fresh capital will fund the completion of its ongoing US FDA Phase 1 study, the launch of Phase 1B expansion cohorts, and global Phase 2 studies — including in India.
"Early clinical data from the ongoing Phase 1 study of ZM008 highlight the differentiated potential of novel NK checkpoint therapy for solid tumors," chief scientific officer Maloy Ghosh said. "We are expanding into dose expansion cohorts and combination studies across multiple tumor types."
Why now? Zumutor's timing aligns with a broader Indian government push to grow the country's biotech sector. Finance minister Nirmala Sitharaman announced the "Biopharma SHAKTI" scheme this year with an outlay of ₹10,000 crore, and the government offers funding and incubation support to biotech startups through the BIRAC SEED programme.
India's bioeconomy is projected to become a $300B market opportunity by 2030, drawing increased investor attention to the sector.
What could go wrong? Drug development is notoriously risky. ZM008 is still in early-stage trials, and moving from Phase 1 to successful Phase 2 results is far from guaranteed. At $7.3M, the round is modest by clinical-trial standards — advancing a drug through multiple study phases globally could require significantly more capital.
Zumutor previously raised $6.2M in a Series A4 round led by Siana Capital in 2021, meaning it has raised relatively little for a company now entering multi-geography trials.
The signal: Premji Invest's entry as a new backer is notable — the investment arm of WiproDealroom has a profile for this one. Try Dealroom → founder Azim Premji's family office adds a heavyweight name to a cap table that already includes Accel, signalling growing institutional confidence in India's nascent immuno-oncology space. With Zumutor still classified as a "breakout stage" company on Dealroom despite being over a decade old, its progression into multi-geography Phase 2 trials will be a key test of whether Indian-origin biotechs can compete in clinical-stage drug development at a global level.
